MEEX Speaker



Head of ADME and Bioanalysis, DMPK Cardiovascular, Renal and Metabolism, AstraZeneca, Sweden


Constanze Hilgendorf holds a Pharmacist license and received her PhD in Pharmaceutical Chemistry and Pharmacokinetics from Martin-Luther University Halle-Wittenberg, Germany in 1999, in collaboration with Astra Hässle, Sweden and the University of Michigan, AnnArbor, USA. After working in contract research in Germany, she joined AstraZeneca R&D in Sweden in 2002. Since then she held a range of scientific and leadership roles, as DMPK drug project lead as well as ADME expert supporting all therapy areas with expertise in drug disposition and DDI. She is currently head of ADME and Bioanalysis in Cardiovascular, Renal and Metabolism (CVRM) DMPK, supporting both drug discovery and development portfolio for all drug modalities, accountable for experimental ADME science strategies, and education and training of DMPK-scientists. Her core scientific interests are the development of translatable in-vitro ADME models (drugtransporters, organ disposition, PGx, and DDI), combined with understanding of impact of disease on organ function and interspecies differences. She has published more than 30 peer reviewed research papers from all aspects of ADME, from SAR of permeability and transport beyond rule-of-five, MS imaging of intestinal absorption, or PBPK-modelling of hepatic drug disposition.